RE: Lisata7 May 2024 09:20
IMM about $20 million on their Phase 2
But...maybe IQAI have no intention of launching a Phase 2. The EAP is their stated objective. So an EAP in territory after territory will bring in some income? Make the drug attractive so someone else will pick it up? Or just give IB tremendous prestige - they will have managed to launch a successful drug, that is actually being used, to save lives, on a shoestring. That is quite something. And they are now besties with the FDA - who owe them a favor with the MRI biz.
Have IQAI given us any numbers on potential revenue? Just that $100 million figure on a PRV that can be sold/transferred - which perhaps that suggests they want the EAP up and running, perhaps globally, then see if they pull off a license deal - or, just let it sit as an EAP type drug? I don't know much about the latter situation, like can a drug be made available for years and years under EAP programs and never go to further trials?
Either way 2024 should be news rich and very interesting. And 2025....